Pemetrexed Followed by Docetaxel or in Reverse Sequence

• ClinicalTrials.gov Identifier: NCT01442909
• Recruitment Status: Completed
• First Posted: September 29, 2011
• Last Update Posted: September 29, 2011
• Sponsor: Taipei Veterans General Hospital, Taiwan
• Information provided by (Responsible Party): Taipei Veterans General Hospital, Taiwan

Study Description

Brief Summary:

Both pemetrexed and docetaxel have been reported to have similar activity against non-small cell lung cancer (NSCLC) who failed previous chemotherapy in a large randomized phase III study. However, no study showed different toxicity and efficacy profiles within individual patients. Present phase II randomized clinical trial is designed to answer these questions, with addition of information about whether or not sequential therapy can prolong disease-free and overall survival.

Condition or disease	Intervention/treatment	Phase
Non-small-cell Lung Cancer	Drug: Docetaxel and pemetrexed	Phase 4

Detailed Description:

Docetaxel was the first third-generation anti-cancer drug found to have activity in second-line chemotherapy for NSCLC, with a prolongation of patient survival in phase III randomized trials comparing docetaxel with vinorelbine or ifosfamide, or with the best supportive care, for NSCLC patients who have failed previous chemotherapy; thus, it has been recommended for the second-line treatment of NSCLC. Four years after these trials, pemetrexed showed similar activity with less toxicity, when compared with docetaxel treatment in a phase III randomized trial of NSCLC patients previously treated with chemotherapy.

Pemetrexed is a multitargeted antifolate which exhibits clinical activity in a variety of solid tumors, especially malignant mesothelioma and NSCLC. It inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. Pemetrexed has confirmed activity against previously chemotherapy-treated NSCLC and has a better toxicity profile than docetaxel, in which study docetaxel dosage used was 75 mg/m2 intravenous infusion (IV) every 3 weeks. However, docetaxel dosage used in Japan and Taiwan is usually 60 mg/m2 every 3 weeks.

Whether or not toxicity profiles of these two different drugs in same individual patients is similar to findings of patients who received specific drug only is unknown, so is unknown of toxicity profiles of docetaxel 60 mg/m2 every 3 weeks comparing alimta 500 mg/m2 every 3 weeks. Present phase II randomized clinical trial is designed to answer these questions, with addition of information about whether or not sequential therapy can prolong disease-free and overall survival.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 44 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy
• Study Start Date: March 2008
• Actual Primary Completion Date: September 2009
• Actual Study Completion Date: September 2009

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: D followed by P; Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).	Drug: Docetaxel and pemetrexed; docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.; Other Names: taxotere; alimta
Active Comparator: P followed by D; Pemetrexed treatment followed by docetael (in reverse sequence of Arm "D followed by P"	Drug: Docetaxel and pemetrexed; docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.; Other Names: taxotere; alimta

Outcome Measures

Primary Outcome Measures :

1. Incidence of grade III or IV leukopenia during treatment [ Time Frame: one year ]

Secondary Outcome Measures :

1. progression-free survival [ Time Frame: one year ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. histologically or cytologically confirmed non-small cell bronchogenic carcinoma, inoperable stage IIIB or IV
2. aged 18 years or older
3. failed previous platinum-based chemotherapy
4. presence of at least one measurable disease which is defined as lesion that can be measured in at least 1 dimension as ≥ 20 mm with conventional CT or ≥ 10 mm with spiral CT scan
5. performance status of Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
6. white blood cell (WBC) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelets ≥ 100,000/mm3 and hemoglobin ≥ 10 mg / dl
7. serum creatinine level 2.0 mg/dL or lower
8. serum bilirubin less than 1.5 times the upper limit of normal range (ULN)
9. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 3 times the ULN (less than 5 times the ULN in liver metastases)
10. written informed consent to participate in the trial In addition, in female patient with childbearing potential, either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine contraceptive device [IUD], birth control pills, or barrier device) during and for three months after trial. Patients who previously treated by surgery are needed to demonstrate progressive disease before entering the study.

Exclusion Criteria:

1. Active infection (at the discretion of the investigator).
2. Active central nervous system (CNS) metastases.
3. Breast feeding.
4. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
5. Use of any investigational agent in the month before enrollment into the study.
6. Concomitant myelosuppressive radiotherapy to target lesion, chemotherapy, hormonal therapy, or immunotherapy will not be allowed.

Contacts and Locations

Locations

Taiwan

Taipei VGH

Taipei City, Taiwan, 112

Sponsors and Collaborators

Taipei Veterans General Hospital, Taiwan

Investigators

• Principal Investigator: Yuh-Min Chen, MD, PhD.; Chest Department, Taipei VGH

More Information

• Responsible Party: Taipei Veterans General Hospital, Taiwan
• ClinicalTrials.gov Identifier: NCT01442909 History of Changes
• Other Study ID Numbers: 97-02-09
• First Posted: September 29, 2011
• Last Update Posted: September 29, 2011
• Last Verified: September 2011

Keywords provided by Taipei Veterans General Hospital, Taiwan:

lung cancer; docetaxel; pemetrexed

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Docetaxel; Pemetrexed; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Folic Acid Antagonists; Nucleic Acid Synthesis Inhibitors